Analysts have revised their price target for Lisata Therapeutics from $20.67 to $13.00, citing updated financial assumptions and outlook.
What's in the News
- Lisata Therapeutics and Catalent have entered a global product license agreement, granting Catalent non-exclusive rights to develop and commercialize bioconjugate products containing certepetide using the SMARTag technology platform. (Key Developments)
- Certepetide, Lisata's proprietary cyclic peptide, has shown potential to enhance the effectiveness of anti-cancer agents through improved tumor targeting and penetration. (Key Developments)
- Lisata is eligible to receive over $10 million in milestone payments, as well as revenue sharing on sales and partnerships arising from the agreement with Catalent. (Key Developments)
- Encouraging preliminary data from a Phase 1/2a clinical trial of certepetide combined with FOLFIRINOX therapies for pancreatic, colon, and appendiceal cancers were announced. Further results will be presented at an upcoming conference. (Key Developments)
- Certepetide has received multiple regulatory designations, including Fast Track and Orphan Drug status for various cancers in the U.S. and E.U., as well as Rare Pediatric Disease Designation for osteosarcoma. (Key Developments)
Valuation Changes
- The consensus analyst price target has fallen significantly from $20.67 to $13.00 per share.
- The discount rate has risen slightly, now at 6.97% compared to the previous 6.78%.
- Revenue growth expectations have increased, with the projected rate moving from 78.6% to 83.8%.
- Net profit margin has declined moderately, dropping from 16.06% to 14.37%.
- The future P/E ratio has decreased meaningfully, from 231.36x to 166.60x.
Have other thoughts on Lisata Therapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.